Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Translate Bio Stock Is Rocketing Higher Today

By Cory Renauer – Updated Jun 23, 2020 at 12:49PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's collaboration with Sanofi is shifting into a higher gear.

What happened

Shares of Translate Bio (TBIO), a clinical-stage biotechnology company, jumped today after the company announced an expanded partnership with Sanofi (SNY 0.05%) that includes the development of a coronavirus vaccine candidate. Investors excited about the collaboration expansion pushed the stock 45.6% higher as of 10:38 a.m. EDT on Tuesday.

So what 

Sanofi and Translate Bio have been working together to develop messenger RNA (mRNA) vaccines for undisclosed diseases since 2018. In March, the two expanded their partnership beyond the original agreement to include an mRNA vaccine candidate directed against SARS-CoV-2, the virus that causes COVID-19.

Person in a jetpack.

Image source: Getty Images.

Translate Bio stock is surging today because Sanofi has taken their collaboration much further. The pharma giant will give Translate $425 million up front for exclusive rights to multiple infectious disease vaccines, including a SARS-CoV-2 candidate. Translate is eligible to receive tiered royalty payments based upon worldwide sales of any successful vaccines at an undisclosed percentage, and milestone payments that could add up to $1.9 billion in total.

Now what

Sanofi will pay for all costs during the term of the collaboration. The partners are currently evaluating multiple SARS-CoV-2 vaccine candidates, but they probably won't select one to advance into human proof-of-concept trials until the fourth quarter of 2020.

Translate Bio finished March with $155 million in cash and securities on its balance sheet after losing $14 million during the first three months of 2020. With Sanofi paying the bills for the development of its vaccines, Translate can turn its attention back to its cystic fibrosis program.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Translate Bio, Inc. Stock Quote
Translate Bio, Inc.
TBIO
Sanofi Stock Quote
Sanofi
SNY
$38.02 (0.05%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.